RESPONSE PREDICTION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TARGETED THERAPY AND/OR IMMUNE CHECKPOINT INHIBITORS

In recent years, major improvements have been achieved in the treatment of metastatic clear-cell renal cell carcinoma with the introduction of angiogenesis-inhibitors and immune therapy. Despite highly variable patient responses, no markers for patient treatment selection have entered the clinic thus far. We aim to search for predictive biomarkers in order to select the right patient for the right therapy. This will allow us to obtain better treatment results, to save adverse events in patients in whom the therapy would not work and to use in a more efficient way public finances. We will search for biomarkers through an extensive study of the molecular characteristics of primary kidney tumors and their metastases and genetic characteristics of the patient. We aim to offer an easy way to classify paraffin embedded kidney tumors into our molecular ccrcc1-4 classification, that has a proven prognostic and predictive impact in different therapeutic situations.

Keywords:Kidney Cancer, Metastases, Angiogenesis inhibitors, Immune checkpoint inhibitors, Predictive biomarkers

Disciplines:Cancer therapy, Cancer biology